Aarti Drugs receives EIR from USFDA for Tarapur API facility

This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP

Aarti Drugs posts Q2 FY25 consolidated profit at Rs. 35.01 Cr

Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024

Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr

The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023

Aarti Drugs Q2 FY24 consolidated net profit drops QOQ to Rs. 39.59 Cr

Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023

Aarti Drugs bags Pharmexcil Outstanding Exports Awards 2021-22

The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23

Aarti Drugs Q3 FY23 revenue grows 4%

Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY